Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced an agreement with Israel-based Ornat Biochemicals and Laboratory Equipment to extend Parse’s reach in the Middle East.
“The past year has represented a considerable leap forward for Parse, with demand growing significantly for our Evercode single cell sequencing solutions,” noted Parse CEO and co-founder Alex Rosenberg, Ph.D. “Partnering with a premier distributor in the Middle East positions us well in the region for continued growth.”
Parse’s agreement with Ornat will give researchers in Israel access to its full single cell portfolio, including Evercode™ Whole Transcriptome, Evercode TCR, Evercode Cell Fixation, Evercode Nuclei Fixation, Gene Capture, and the Parse Biosciences data analysis solution. The agreement bolsters Parse’s plan to offer its products in key international markets.
“Parse is accelerating the pace of single cell research with its Evercode technology. We're elated to partner with them to introduce this state of the art technology to the thriving biotech community in Israel,” said Ornat CEO, Eyal Lev.
About Parse Biosciences
Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.
With technology developed at The University of Washington by co-founders Alex Rosenberg and Charles Roco, Parse has raised over $50 million in capital and is now used by nearly 1,000 customers across the world. Its growing portfolio of products includes Evercode Whole Transcriptome, Evercode TCR, Gene Capture, and a data analysis solution.
Parse Biosciences is based in Seattle’s vibrant South Lake Union district, where it recently opened a 34,000 square foot headquarters and state-of-the-art laboratory. To learn more, please visit https://www.parsebiosciences.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005438/en/
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-PSMF3.6.2023 07:12:31 CEST | Press release
The Patient Safety Movement Foundation Concludes Its 10th Annual World Patient Safety, Science & Technology Summit
HALLYM-UNIVERSITY2.6.2023 11:01:34 CEST | Press release
Ilsong Educational Foundation Chairman Dai-Won Yoon Wins Linnaeus Medal as the First in Asia
CA-PSMF2.6.2023 08:16:30 CEST | Press release
10th Annual World Patient Safety, Science & Technology Summit Begins
AUTEL-ENERGY2.6.2023 08:01:28 CEST | Press release
Autel Energy Holds Partner Summit in Amsterdam, Mapping Out Europe Strategy
PL-BIOSCIENCE-GMBH2.6.2023 07:23:26 CEST | Press release
PL BioScience and Macopharma enter into a Patent License and Assignment Agreement regarding Human Platelet Lysate (HPL) cell culture supplements.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom